Clinical value of vascular endothelial growth factor and endostatin in urine for diagnosis of bladder cancer

Tumori

Volumn 98, Issue 6, 2012, Pages 762-767

  Cheng, Daye ^a   Liang, Bin ^a   Li, Yunhui ^b  

^a CHINA MEDICAL UNIVERSITY   (China)

^b No 202 Hospital of PLA   (China)

Author keywords

Bladder cancer; Diagnosis; Endostatin; Urine; Vascular endothelial growth factor

Indexed keywords

ENDOSTATIN; TUMOR MARKER; VASCULOTROPIN;

ADULT; ARTICLE; BLADDER CARCINOMA; CANCER CYTODIAGNOSIS; CANCER DIAGNOSIS; CANCER GRADING; CANCER GROWTH; CANCER PROGNOSIS; CANCER STAGING; CANCER SURVIVAL; COMPARATIVE STUDY; CONTROLLED STUDY; DIAGNOSTIC TEST ACCURACY STUDY; DIAGNOSTIC VALUE; ENZYME IMMUNOASSAY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MOLECULAR DIAGNOSIS; ONCOLOGICAL PARAMETERS; PREDICTIVE VALUE; RECEIVER OPERATING CHARACTERISTIC; SENSITIVITY AND SPECIFICITY; SURVIVAL RATE; SURVIVAL TIME; TUMOR NUMBER; TUMOR VOLUME; URINALYSIS; URINARY TRACT DISEASE; URINE CYTOLOGY; URINE LEVEL;

ADULT; AGED; ASIAN CONTINENTAL ANCESTRY GROUP; CHINA; DISEASE PROGRESSION; ENDOSTATINS; FEMALE; HUMANS; KAPLAN-MEIER ESTIMATE; MALE; MIDDLE AGED; NEOPLASM GRADING; NEOPLASM STAGING; PREDICTIVE VALUE OF TESTS; PROGNOSIS; TUMOR MARKERS, BIOLOGICAL; URINARY BLADDER NEOPLASMS; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 84873625229     PISSN: 03008916     EISSN: 20382529     Source Type: Journal    
DOI: 10.1177/030089161209800614     Document Type: Article

References (28)

1. Parkin DM, Bray F, Ferlay J, Pisani P: Global cancer statistics, 2002. CA Cancer J Clin, 55: 74-108, 2005.
2. Muller M: Telomerase: its clinical relevance in the diagnosis of bladder cancer. Oncogene, 21: 650-655, 2002.
3. Sturgeon CM, Duffy MJ, Hofmann BR, Lamerz R, Fritsche HA, Gaarenstroom K, Bonfrer J, Ecke TH, Grossman HB, Hayes P, Hoffmann RT, Lerner SP, Lohe F, Louhimo J, Sawczuk I, Taketa K, Diamandis EP: National Academy of Clinical Biochemistry Laboratory Medicine Practice Guidelines for use of tumor markers in liver, bladder, cervical, and gastric cancers. Clin Chem, 56: 31-48, 2010.
4. Bernardini S, Fauconnet S, Chabannes E, Henry PC, Adessi G, Bittard H: Serum levels of vascular endothelial growth factor as a prognostic factor in bladder cancer. J Urol, 166: 1275-1279, 2001.
5. Wang HF, Wang JS: Research progress in potential urinary markers for the early detection, diagnosis and follow-up of human bladder cancer. Asian Pacific J Cancer Prevent (APJCP), 13: 1723-1726, 2012.
6. Nyberg P, Xie L, Kalluri R: Endogenous inhibitors of angiogenesis. Cancer Res, 65: 3967-3979, 2005.
7. Crew JP, O'Brien T, Bicknell R, Fuggle S, Cranston D, Harris AL: Urinary vascular endothelial growth factor and its correlation with bladder cancer recurrence rates. J Urol, 161: 799-804, 1999.
8. O'Reilly MS, Boehm T, Shing Y, Fukai N, Vasios G, Lane WS, Flynn E, Birkhead JR, Olsen BR, Folkman J: Endostatin: an endogenous inhibitor of angiogenesis and tumor growth. Cell, 88: 277-285, 1997.
9. Szarvas T, Laszlo V, Dorp FV, Reis H, Szendroi A, Romics I, Tilki D, Rubben H, Ergun S: Serum endostatin levels correlate with enhanced extracellular matrix degradation and poor patients' prognosis in bladder cancer. Int J Cancer, 130: 2922-2929, 2012.
10. Hanley JA, McNeil BJ: The meaning and use of the area under a receiver operating characteristic (ROC) curve. Radiology, 143: 29-36, 1982.
11. Eissa S, Kassim S, El-Ahmady O: Detection of bladder tumours: role of cytology, morphology-based assays, biochemical and molecular markers. Curr Opinion Obstet Gynecol, 15: 395-403, 2003.
12. Shariat SF, Karam JA, Lerner SP: Molecular markers in bladder cancer. Curr Opinion Urol, 18: 1-8, 2008.
13. Cressey R, Wattananupong O, Lertprasertsuke N, Vinitketkumnuen U: Alteration of protein expression pattern of vascular endothelial growth factor (VEGF) from soluble to cell-associated isoform during tumourigenesis. BMC Cancer, 5: 128, 2005.
14. Kitadai Y: Angiogenesis and lymphangiogenesis of gastric cancer. J Oncol, 2010: 468725, 2010.
15. Santos L, Costa C, Pereira S, Koch M, Amaro T, Cardoso F, Guimaraes T, Bento MJ, Lobo F, Pinto S, Lopes C: Neovascularisation is a prognostic factor of early recurrence in T1/G2 urothelial bladder tumours. Ann Oncol, 14: 1419-1424, 2003.
16. El-Chennawi FA, Auf FA, Metwally SS, Mosaad YM, Shaaban AA, El-Baz MA, Tawhid ZE, Lotfy ZF: Vascular endothelial growth factor, p53, and the H-ras oncogene in Egyptian patients with bladder cancer. World J Gastrointest Oncol 1: 62-68, 2009.
17. Harper J, Yan L, Loureiro RM, Wu I, Fang J, D'Amore PA, Moses MA: Repression of vascular endothelial growth fac- tor expression by the zinc finger transcription factor ZNF24. Cancer Res, 67: 8736-8741, 2007.
18. Gerber HP, Hillan KJ, Ryan AM, Kowalski J, Keller GA, Rangell L, Wright BD, Radtke F, Aguet M, Ferrara N: VEGF is required for growth and survival in neonatal mice. Development, 126: 1149-1159, 1999.
19. Xie K, Wei D, Shi Q, Huang S: Constitutive and inducible expression and regulation of vascular endothelial growth factor. Cytokine Growth Factor Rev, 15: 297-324, 2004.
20. Wilson RF, Morse MA, Pei P, Renner RJ, Schuller DE, Robertson FM, Mallery SR: Endostatin inhibits migration and invasion of head and neck squamous cell carcinoma cells. Anticancer Res, 23: 1289-1295, 2003.
21. Nakanishi R, Oka N, Nakatsuji H, Koizumi T, Sakaki M, Takahashi M, Fukumori T, Kanayama HO: Effect of vascular endothelial growth factor and its receptor inhibitor on proliferation and invasion in bladder cancer. Urol Int, 83: 98-106, 2009.
22. Schips L, Dalpiaz O, Lipsky K, Langner C, Rehak P, Puerstner P, Pummer K, Zigeuner R: Serum levels of vascular endothelial growth factor (VEGF) and endostatin in renal cell carcinoma patients compared to a control group. Eur Urol, 51: 168-174, 2007.
23. Nielsen ME, Schaeffer EM, Veltri RW, Schoenberg MP, Getzenberg RH: Urinary markers in the detection of bladder cancer: what's new? Curr Opinion Urol, 16: 350-355, 2006.
24. Gray M, Sims TW: NMP-22 for bladder cancer screening and surveillance. Urol Nursing, 24: 171-186, 2004.
25. Topsakal M, Karadeniz T, Anac M, Donmezer S, Besisik A: Assessment of fibrin-fibrinogen degradation products (Accu-Dx) test in bladder cancer patients. Eur Urol, 39: 287-291, 2001.
26. Bravaccini S, Sanchini MA, Granato AM, Gunelli R, Nanni O, Amadori D, Calistri D, Silvestrini R: Urine telomerase activity for the detection of bladder cancer in females. J Urol, 178: 57-61, 2007.
27. Sylvester RJ, van der Meijden AP, Oosterlinck W, Witjes JA, Bouffioux C, Denis L, Newling DW, Kurth K: Predicting recurrence and progression in individual patients with stage Ta T1 bladder cancer using EORTC risk tables: a combined analysis of 2596 patients from seven EORTC trials. Eur Urol, 49: 466-467, 2006.
28. Yun SJ, Jo SW, Ha YS, Lee OJ, Kim WT, Kim YJ, Lee SC, Kim WJ: PFKFB4 as a prognostic marker in non-muscle-invasive bladder cancer. Urol Oncol, 2011.